Biden wants to cover weight loss meds. RFK Jr. would rather we just eat better.
The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr. may not be such a fan.
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.
Medications, Including Injectable Weight-Loss Drugs, Make Up One-Third of VA's Projected 2025 Budget Shortfall
Under Secretary for Health Dr. Shereef Elnahal said Monday the VA needs extra funding to cover the costs of drugs such as Ozempic and Wegovy, which the Biden administration announced Tuesday should be covered for Medicare patients.
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Biden proposes Medicare and Medicaid cover weight-loss drugs for obese Americans
Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday mornin
Should Medicare, Medicaid Cover Anti-Obesity Drugs? Doctors Speak Out
Joe Biden wants diabetes drugs that aid weight loss and treat obesity, such as Wegovy, to fall under Medicare and Medicaid.
Biden proposes Medicare, Medicaid cover pricey weight-loss drugs for obese Americans
Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."
What to Know About Biden’s Plan for Weight-Loss Drugs, Medicaid and Medicare
The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
Biden administration calls for Medicare and Medicaid to cover drugs used for weight loss
The Biden administration called for Medicare and Medicaid to cover popular drugs that help people lose weight but are not affordable for many Americans who might benefit from them. NBC News' Stephanie Gosk reports.
Investor's Business Daily on MSN4d
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound
Amgen stock crashed Tuesday after its highly anticipated weight-loss drug met Wall Street's expectations, but didn't beat ...
Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...
How to preserve muscle mass on weight-loss drugs like Wegovy
There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...
Study: Weight-loss meds like Ozempic might increase food waste
America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, ...
valuepenguin4d
Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs
For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the same main ingredient as Mounjaro. The difference is that Mounjaro is for diabetes and Zepbound ...
Healthline5d
Weight Loss Medications: A Dietitian Explains Everything You Need to Know
Currently, only liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) are approved for weight loss, though some other GLP-1 drugs may be prescribed off-label. Keep in mind that ...
UPI9d
Weight-loss drug Zepbound might help manage heart failure
Eli Lilly, maker of Zepbound, sponsored the trial ... more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. Back to top ...